Regorafenib in Combination With Silybin as a Novel Potential Strategy for the Treatment of Metastatic Colorectal Cancer

Oncotarget - United States
doi 10.18632/oncotarget.20054
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer

Patient Preference and Adherence
PharmacologyHealth PolicyMedicineToxicologySocial SciencesPharmaceutics
2019English

Angiogenesis Genotyping and Clinical Outcome During Regorafenib Treatment in Metastatic Colorectal Cancer Patients

Scientific Reports
Multidisciplinary
2016English

Regorafenib Adjusted Dose for Chilean Patients With Chemoresistant Metastatic Colorectal Cancer: A Case Series

ecancermedicalscience
Cancer ResearchOncology
2018English

KDR Gene as a Predictive Biomarker of Response to Regorafenib in Patients With Metastatic Colorectal Cancer (mCRC)

Journal of Pharmacogenomics & Pharmacoproteomics
2017English

A Systematic Review and Meta-Analysis of Retrospective Series of Regorafenib for Treatment of Metastatic Colorectal Cancer

Anticancer Research
MedicineCancer ResearchOncology
2017English

Regorafenib Okayed for Colorectal Cancer

Cancer Discovery
Oncology
2012English

Response to Regorafenib at an Initial Dose of 120 Mg as Salvage Therapy for Metastatic Colorectal Cancer

Molecular and Clinical Oncology
Cancer ResearchOncology
2017English

Safety and Efficacy of Regorafenib in Patients With Treatment-Refractory Metastatic Colorectal Cancer in Turkey: The Single-Arm, Open-Label REGARD Study

BMJ Open
Medicine
2020English

Real‐World Adherence in Patients With Metastatic Colorectal Cancer Treated With Trifluridine Plus Tipiracil or Regorafenib

Oncologist
Cancer ResearchMedicineOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy